The DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.
Copper-64 Radiopharmaceuticals for PET Imaging of Cancer: Advances in Preclinical and Clinical Research
Open accessAbstract
Copper-64 (T(1/2) = 12.7 hours; beta(+), 0.653 MeV [17.8 %]; beta(-), 0.579 MeV [38.4 %]) has decay characteristics that allow for positron emission tomography (PET) imaging and targeted radiotherapy of cancer. The well-established coordination chemistry of copper allows for its reaction with a wide variety of chelator systems that can potentially be linked to peptides and other biologically relevant small molecules, antibodies, proteins, and nanoparticles. The 12.7-hours half-life of 64Cu provides the flexibility to image both smaller molecules and larger, slower clearing proteins and nanoparticles. In a practical sense, the radionuclide or the 64Cu-radiopharmaceuticals can be easily shipped for PET imaging studies at sites remote to the production facility. Due to the versatility of 64Cu, there has been an abundance of novel research in this area over the past 20 years, primarily in the area of PET imaging, but also for the targeted radiotherapy of cancer. The biologic activity of the hypoxia imaging agent, 60/64Cu-ATSM, has been described in great detail in animal models and in clinical PET studies. An investigational new drug application for 64Cu-ATSM was recently approved by the U.S. Food and Drug Administration (FDA) in the United States, paving the way for a multicenter trial to validate the utility of this agent, with the hopeful result being FDA approval for routine clinical use. This article discusses state-of-the-art cancer imaging with 64Cu radiopharmaceuticals, including 64Cu-ATSM for imaging hypoxia, 64Cu-labeled peptides for tumor-receptor targeting, (64)Cu-labeled monoclonal antibodies for targeting tumor antigens, and 64Cu-labeled nanoparticles for cancer targeting. The emphasis of this article will be on the new scientific discoveries involving (64)Cu radiopharmaceuticals, as well as the translation of these into human studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Calcium's Role in Mechanotransduction during Muscle Development
Benavides Damm, T., & Egli, M. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000356667 · Cited by 14,502
Integrins: Versatility, modulation, and signaling in cell adhesion
Hynes, R. O. (1992) · Cell · doi:10.1016/0092-8674(92)90115-s · Cited by 9,859
Multifunctional Inorganic Nanoparticles for Imaging, Targeting, and Drug Delivery
Liong, M., Lu, J., Kovochich, M., Xia, T., Ruehm, S. G., Nel, A. E., Tamanoi, F., & Zink, J. I. (2008) · ACS Nano · doi:10.1021/nn800072t · Cited by 1,929
Role of integrins in cell invasion and migration
Hood, J. D., & Cheresh, D. A. (2002) · Nature Reviews Cancer · doi:10.1038/nrc727 · Cited by 1,777
Höckel, M., Schlenger, K., Aral, B., Mitze, M., Schäffer, U., & Vaupel, P. W. (1996) · PubMed · Cited by 1,727
Xiong, J.-P., Stehle, T., Zhang, R., Joachimiak, A., Frech, M., Goodman, S. L., & Arnaout, M. A. (2002) · Science · doi:10.1126/science.1069040 · Cited by 1,613
In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice
Liu, Z., Cai, W., He, L., Nakayama, N., Chen, K., Sun, X., Chen, X., & Dai, H. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2006.170 · Cited by 1,436
Copper biochemistry and molecular biology
Linder, M. C., & Hazegh-Azam, M. (1996) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/63.5.797 · Cited by 1,430
Dendrimers and dendritic polymers in drug delivery
Gillies, E. R., & Fréchet, J. M. J. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03276-3 · Cited by 1,367
SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action
Bauer, W., Briner, U., Doepfner, W., Haller, R., Huguenin, R., Marbach, P., Petcher, T. J., & Pless, J. (1982) · Life Sciences · doi:10.1016/0024-3205(82)90087-x · Cited by 1,331
Metadata
- Authors
- Anderson, C. J., & Ferdani, R.
- Venue
- Cancer Biotherapy and Radiopharmaceuticals
- Publisher
- SAGE Publications
- Published
- 2009-08
- Volume
- 24
- Issue
- 4
- Pages
- 379-393
- ISSN
- 1084-9785 (ISSN-L)
- 1557-8852
- OpenAlex
- W2137792756
- Cited by
- 374
- References
- 96
- FWCI
- 8.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Copper-64 Radiopharmaceuticals for PET Imaging of Cancer: Advances in Preclinical and Clinical Research. https://app.cochat.ai/papers/10.1089/cbr.2009.0674
- The paper
- Anderson, C. J., & Ferdani, R. (2009). Copper-64 Radiopharmaceuticals for PET Imaging of Cancer: Advances in Preclinical and Clinical Research. Cancer Biotherapy and Radiopharmaceuticals. https://doi.org/10.1089/cbr.2009.0674
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.